Neumora Therapeutics, Inc. (NMRA)
0.427
+0.07
(+20.45%)
USD |
NASDAQ |
Oct 15, 16:00
0.459
+0.03
(+7.49%)
Pre-Market: 08:02
Neumora Therapeutics Research and Development Expense (Quarterly) : 29.28M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.28M |
| March 31, 2026 | 38.60M |
| December 31, 2025 | 44.67M |
| September 30, 2025 | 40.52M |
| June 30, 2025 | 38.72M |
| March 31, 2025 | 52.15M |
| December 31, 2024 | 45.91M |
| September 30, 2024 | 60.63M |
| June 30, 2024 | 48.63M |
| March 31, 2024 | 45.76M |
| Date | Value |
|---|---|
| December 31, 2023 | 38.86M |
| September 30, 2023 | 41.60M |
| June 30, 2023 | 32.77M |
| March 31, 2023 | 29.48M |
| December 31, 2022 | 23.52M |
| September 30, 2022 | 22.55M |
| June 30, 2022 | 23.53M |
| March 31, 2022 | 22.15M |
| March 31, 2021 | 11.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioAge Labs, Inc. | 24.36M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |
| Johnson & Johnson | 4.652B |